Recently, we also investigated the effects of S100A9 inhibitor tasquinimod, currently evaluated in clinical trial for relapsed/refractory MM patients and observed a clear reduction in the M-MDSC subset in vivo (NCT04405167). Here, S100A9 is linked to Miyoshi myopathy.